Back to search

University of British Columbia

Epigenetic dysregulation in synovial sarcoma

Abstract

dc:description

Synovial sarcoma is an aggressive soft tissue malignancy characterized by a pathognomonic chromosomal translocation leading to the production of SS18-SSX, a fusion oncoprotein which associates with BAF, a chromatin remodelling complex. BAF complexes exist in three main subtypes and recent research demonstrated that SS18-SSX drives the degradation of cBAF, leading to a relative increase in ncBAF and PBAF. I analyzed 31 cases of primary human synovial sarcoma using ChIP-seq for histone modifications, RNA-seq for transcriptomes, and whole genome bisulfite sequencing for DNA methylomes. In addition, I analyzed chromatin accessibility in 14 cases using scATAC-seq. Unsupervised hierarchical clustering of ChIP-seq density for active histone modifications (H3K27ac, H3K4me1, H3K4me3) reveals two major synovial sarcoma epigenetic subgroups: “Group 1” and “Group 2”. Enhancers from Group 1 tumors show lower levels of cBAF binding compared to enhancers from Group 2 tumors. Group 1 enhancers also show greater overlap with binding sites of oncogenic BAF complexes (from cell lines containing SS18-SSX) compared to non-oncogenic BAF complexes (from cell lines with SS18-SSX knockdown). Therefore, the differences in these subgroups could be driven by differences in SS18-SSX activity. This led to my hypothesis that synovial sarcomas can be subgrouped based on epigenomic state, and this relates to disease severity. In support, I demonstrate that Group 1 tumors are higher grade sarcomas and that treating synovial sarcoma cells with a histone deacetylase inhibitor or knockdown of SS18-SSX both cause proliferative arrest and increase the expression of Group 2 enhancer associated genes. scATAC-seq analyses reveal a rare cluster of cells (6%) shared among all tumors. These cells express SS18-SSX yet differ from all other malignant cells in their expression of synovial sarcoma signature genes, as predicted by open chromatin. The chromatin state of these cells is more correlated with the lower grade subgroup (Group 2) compared to higher grade subgroup (Group 1). These cells may therefore represent an intermediate/early malignant cell state. Overall, my analysis suggests that human synovial sarcomas can be classified by epigenomic state, which may reflect the activity of SS18-SSX. My findings are relevant for guiding emerging therapeutic strategies that target BAF complex imbalances.

Degree

thesis:*
Name thesis:degree_name
Doctor of Medicine / Doctor of Philosophy - MD/PhD
Level thesis:degree_level
doctoral
Discipline thesis:degree_discipline
Interdisciplinary Oncology
Grantor dc:publisher
University of British Columbia
Year dc:date
2022

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Qiu, Alvin
Contributors dc:contributor
  • Hirst, Martin
  • Nielsen, Torsten

Rights

dc:rights
Statement dc:rights
  • Attribution-NonCommercial-NoDerivatives 4.0 International
Language dc:language
eng

Identifiers

dc:identifier.*
Handle dc:identifier
http://hdl.handle.net/2429/81726

Chain of custody

source
Harvested from
University of British Columbia
Base URL
circle.library.ubc.ca/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Qiu, Alvin. Epigenetic dysregulation in synovial sarcoma. doctoral thesis, University of British Columbia, 2022. http://hdl.handle.net/2429/81726